Hos cancerpatienter var den farmakokinetiske profil af Filgrastim ratiopharm og referenceproduktet sammenlignelige efter en enkelt og gentagne subkutane doser.
In cancer patients, the pharmacokinetic profile of Filgrastim ratiopharm and the reference product was comparable after single and repeated subcutaneous administration.